Effects of Orlistat and Herbal Mixture Extract on Renal Function and Oxidative Stress Biomarkers in a Rat Model of High Fat Diet

Kamal A. Amin¹², Sana’a R. Galaly³, Wala’a G. Hozayen⁴ and Shima’a M. Ramadan⁴

¹Biochemistry Department, Faculty of Veterinary medicine, Beni-Suef University, Egypt.
²Chemistry Department, Dammam University, college of Science, Saudi Arabia.
³Zoology Department, Histology, Faculty of Science, Beni-Suef University, Egypt.
⁴Biochemistry-Chemistry Department, Faculty of Science, Beni-Suef University, Egypt.

Authors’ contributions
This work was carried out in collaboration between all authors. Author KAA designed the study, performed the statistical analysis, wrote the protocol, and wrote the first draft of the manuscript. Authors SRG and WGH designed the study, managed the analysis of the study and parts of histopathology and biochemistry. Author SMR managed the literature searches.
All authors read and approved the final manuscript.

ABSTRACT

Aims: This study was designed to assess the effectiveness of herbal mixture extracts of pumpkin seed oil, peanuts shell and Orlistat on renal function and oxidative stress biomarkers in male albino rats administrated high fat diet (HFD).

Study Design: Fifty male rats were divided into four groups: 1st a normal diet, 2nd HFD, 3rd HFD with Orlistat and 4th HFD with herbal mixture.

Place and Duration of Study: Biochemistry-Chemistry department, Faculty of Science, Beni-Suef University for two years.

Methodology: A group of rats were fed with a standard control diet (1st control group) and another group of rats were fed with a diet containing 35% fat (2nd HFD) for 16 weeks. Then, this group of HFD was divided into 3 groups for the following 6 weeks: 1st group had HFD only, 2nd group had HFD plus 2 mg/kg bw/day Orlistat and 3rd group had HFD

*Corresponding author: Email: kaamin10@yahoo.com;
plus 5 mg/kg bw/day pumpkins and 2 mg/kg bw/day nutshell extract. Blood and renal tissues were collected for biochemical assays.

**Results:** HFD group showed a very high significant increase (**P<0.001**) in feed intake from low (216.9+/−12.25) to high (327.5+/−22.00), body weight and body mass index. HFD affect the kidney by increasing serum uric acid (**P<0.01**) (1.964+/−0.251) to (3.106+/−0.161), urea, creatinine, (**P<0.001**) for low density lipoproteins and total cholesterol (16.71+/−2.27 to 55.78+/−4.40 and 70.30+/−2.75 to 118.10+/−6.35) respectively, triacylglycerol (**P<0.01**) (54.60+/−6.42 to 80.00+/−0.65) and malondialdehyde (**P<0.001**) (35.48+/−3.52 to 63.03+/−1.48). These changes improved by the treatments with Orlistat and herbal mixture that decreased the oxidative stress biomarkers.

**Conclusion:** Rats that fed with HFD showed hypertriglyceridemia, increased oxidative stress and renal alteration. Moreover, suggesting association between lipid peroxidation, obesity and nephropathy, while treatment with Orlistat and herbal mixture ameliorated the harmful effects of the HFD and reduce feed intake.

**Keywords:** Obesity; orlistat; plant mixture (pumpkin oil with nutshell extract); hyperlipidemia; renal function; oxidative stress.

**ABBREVIATIONS**

ARF- Acute renal failure; BMI- Body mass index; BUN- Blood urea nitrogen; BW- Body weight; CH- Cholesterol; CKD- Chronic kidney disease; Cre- Creatinine; ESRD- End-stage renal disease; FFA- Free fatty acid; FPSO- Fluted pumpkin seed oil; GFR- Glomerular filtration rate; GSH- Reduced glutathione; HCA- Hydroxy citric acid; HDL- High density lipoprotein; HFD- High fat diet; HO-1- Heme oxygenase-1; HSL- Hormone sensitive lipase; LCF- Lipid Cclearing Factor; LDL- Low density lipoprotein; LPL- Lipoprotein lipase; MDA- Malondialdehyde; Nc- Necrotic cells; ORG- Obesity-related glomerulopathy; PAF- Platelet-activating factor; PL- Pancreatic lipase; PSE- Peanut shell extract; PSO- Pumpkin seed oil; PUFAs- Polyunsaturated fatty acid; RAAS- Reninangiotensin-aldosterone system; ROS- Reactive oxygen species; RPF- Renal plasma flow; RT- Renal tubules; SOD- Superoxide dismutase; TG- Triglyceride; WHO- World health organization; WHR- Waist hip ratio.

1. **INTRODUCTION**

Obesity had been one of the leading public health concerns in industrialized societies for the last 40 years. It had been defined by the WHO as a body mass index or BMI above 30 kg/m² [1]. It was reported that obesity increased the risk of end-stage renal disease (ESRD). Excess weight plays a fundamental role in the development of proteinuria and renal damage to patients with severe renal mass reduction [2]. It was found that feeding of HFD that used as inducer for hypercholesterolemia (that made by adding 30% lard or beef tallow and 5% sunflower to the control diet) caused a significant increase in serum MDA level compared with control group. Oxidative stress had been commonly identified in obesity by” the related renal diseases and may be the mechanism underlying the initiation or progression of renal injury in obesity” [3]. The treatment with Garcinia is similar to Orlistat in there action. It significantly decreased MDA level compared with those in group HFD. Garcinia treatment enhanced renal function as a result of HCA-SX derived from Garciniacambogia which attenuated the increased of oxidative stress biomarkers through reducing lipid peroxidation [4]. On the other hand the treatment with herbal mix showed a decrease in renal function tests and improvement of kidney function.
Pumpkin seed and its oil are rich in unsaturated fatty acid due to high omega-3 fatty acid. Some researches had demonstrated that pumpkin seed oil (PSO) could remarkably reduce bladder pressure, increase bladder compliance and reduce urethral pressure [5]. Peanuts shell contained different bioactive compounds: flavonoids (luteolin and eriodictyolapigenin and chrysin), fatty acids, additional constituents represented by coumarin derivatives (esculetin and daphnetin like compounds) and phenolic acids (coumaric and ferulic acids) [6]. Peanuts shell extract (PSE) showed in vitro inhibitory activity on pancreatic lipase (PL) and lipoprotein lipase (LPL) activity. Also, it was found that PSE had a strong renal protective effect against glycerol-induced acute renal failure (ARF). Pretreatment with PSE in acute renal failure (ARF) rats caused blood urea nitrogen (BUN) and creatinine levels were significantly lower [7]. This study investigates effect of an obesity-associated risk factor on renal oxidative stress, its mechanism of action and biomarkers associated with the effect of Orlistat and herbal mixture on it by the measurement of cholesterol, triglyceride, HDL, LDL, urea, creatinine, uric acid, food consumption, body weight, body mass index, SOD, MDA and GSH in all four groups of experiments, determine the effect of HFD on these parameters and effect of treatments on it.

2. MATERIALS AND METHODS

2.1 Materials

2.1.1 Diet

Two types of diets had been used, control rat chow diet and special HFD (35%) for induction of obesity in rats.

(a) Normal rat chow diet: It was formed according to Kim et al. [8]. The standard normal rat pellet chow consists of concentrate (350 g), corn (600 g), calcium carbonate, dicalcium phosphate, sodium chloride magnesium oxide and vitamins (50 g). Standard normal rat diet composed of 65% CHO (60% starch+5% sucrose), fat 5%, crude protein 20%, vitamins and minerals 5%, fibers 5%, metabolic PSE of this diet is 2813 Kcal/Kg with 8% from fat.

(b) The HFD: composed of 300 g concentrates, 350 corns, 300 g beef tallow, 50 g vitamins, minerals and fibres according to Kim et al. [8]. Percentage of HFD was 20% crude protein, 35% fat, 40% CHO (starch 35%, 5% sucrose) 5% vitamins, minerals and fibres. Metabolic PSE of this diet is 5130 Kcal/kg, 61% of this PSE from fat. Diet of high fat (HFD) would be (lard and sunflower oil) and starch for induction of obesity from local market by adding 30% lard or beef tallow and 5% sunflower to the control diet [8].

2.1.2 Chemicals

Orlistat is a white to off-white crystalline powder. Orlistat is practically insoluble in water, freely soluble in chloroform, and soluble in methanol and ethanol. It is available for oral administration as a dark-blue or turquoise hard-gelatin capsule. Each capsule contains a pellet formulation consisting of 120 mg of the active ingredient, Orlistat, as well as the inactive ingredients microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, povidone, and talc [9]. Orlistat is (S)-2-formylamino-4-methyl-pentanoic acid (S)-1-[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl] methyl dodecyl ester. Its empirical formula is C_{25}H_{53}NO_{5}, and its
molecular weight is 495.7. It was given orally by oral gavage with a dose 2 mg/kg bw/day [10].

2.1.3 Herbal mixture

Mixture herbal extract of ArachicsHypogaea nutshell extract + cucurbitamoschata + morusalb [11] from local market.

1. Pumpkin oils (PO) were purchased from El Kaptin pharmaceutical company; it is a liquid was given by oral gavage in dose of 5mg/kg bw/day [12].
2. Ethanolic extract of Nutshell was prepared by soaking 100 g of dry nutshell in 500 ml ethyl alcohol 95% with daily shaking for 5 days and kept in a refrigerator. Ethanol was evaporated using a rotatory evaporator apparatus which was attached with vacuum pump then the extract was used by dose 2 mg/kg bw/day [11]. Both herbal were mixed together (1:1).

2.2 Methods

2.2.1 Animals grouping

Our experiment continued for 22 week and divided into two phases (induction period and treatment period).

(a) Induction obesity period: It began from 0-16th week; by feeding rats with HFD. The animals were divided into four groups; control, HFD, HFD with Orlistat and HFD with herbal mix group.

(b) Treatment period: It began form 16-22th week during this period, HFD group was divided into three groups, (HFD) group continued on fat diet, (HFD+Orlistat) treated group maintained on HFD to 6 weeks with administration of Orlistat treatment at dose of 2 mg/Kg/bw rat/day by stomach tube. While other group HFD maintained on HFD to 6 weeks with administration of herbal mix treatment at dose of 5 mg/kg/bw rat/day for PO and 2 mg/kg/bw rat/day for nutshell by stomach tube.

This study was carried out on white male albino rats (wistar rats) weighing about 100 ± 20g which were used as experimental animals. Rats were fed with a standard control diet for 22 weeks. In the present investigation, the rats were obtained from the animal house of Research Institute of Ophthalmology, El Giza, Egypt. The rats were kept under observation for about 7 days before the onset of experiment to exclude any intercurrent infection. During the period of the research in the laboratory of Biochemistry, Faculty of Science, Beni Suef University, the chosen animals were housed in plastic container at normal atmospheric temperature (25ºC±5). Food and water were consumed ad libitum. Body weights were recorded weekly and food consumption was calculated daily. Fifty male rats were divided into four groups: 1st a normal diet group (12 rats for control negative maintained on standard normal rat chow diet along the all period of experiment 22 weeks), 2nd HFD group (13 rats HFD) act as control positive, 3rd HFD with 2 mg/kg bw/day Orlistat (12 rats for 6 weeks) and 4th HFD with 5 mg/kg bw/day pumpkins and 2 mg/kg bw/day nutshell extract (13 rats for 6 weeks). Calculation of average food consumption per each rat was recorded daily by subtracting the amount of food remaining in each day from the measured amount of food provided at the previous day [13]. It was known that metabolic energy of standard rat chow and HFD were
2813 and 5130 Kcal/kg respectively, so the average energy intake was calculated by multiplying the average consumed diet by 2.813 and 5.130 respectively [13]. BMI for rats was measured every week and calculated by dividing the body weight in g by the length (nose to base of tail) in cm$^2$. Also, BW was measured.

### 2.2.2 Sampling and tissue preparation

Blood samples were collected from medial canthus of the eye, via glass capillaries at fasting state. The samples were collected in dry glass centrifuge tubes, allowed to coagulate at room temperature and centrifuged at 3500 rpm for 15 minutes at room temperature for separation of serum. The clear, non-haemolysed supernatant sera were separated using clean dry disposable plastic syringes and stored at -20°C for subsequent biochemical measurements.

Tissue sampling: At the end of experiment (22 week), rats were sacrificed by decapitation and abdominal incision was immediately done after taking of blood sample for separation of kidney tissues. Kidney was taken and washed by saline (0.9%), dried by filter paper and weighed 0.5 g of this tissue then underwent homogenization then centrifuged at 3000 rpm for 15 minutes and the supernatant were kept at -20°C for the biochemical tissue analysis of SOD, MDA and GSH. For light microscopic study, the specimens were fixed in 10% neutral-buffered formalin, dehydrated through alcohols, cleared in zylene and then embedded in paraffin wax. Sections (5 μm thick) were stained with haematoxylin and eosin [14].

### 2.3 Experimental Studies

#### 2.3.1 Biochemical examination

Cholesterol activity in serum was determined according to the method of (CHOD-PAP-Method) Enzymatic Colorimetric Test for Cholesterol with Lipid Clearing Factor (LCF) [15] and HDL-C in serum determined according to the method of Precipitant and Standard [16]. Serum TG was estimated by the method of Fossati and Prencipe [17] and GPO-PAP-Method. LDL-C can be calculated by the equation: LDL-C (mg %)=total Cholesterol-(triglyceride/5)+HDL-C. Urea concentration was determined colorimetrically [18]. Also, Creatinine was determined according to kinetic determination of creatinine without serum deproteinization [19]. Uric acid level [20] and GSH level also, measured according to colorimetric method that based on the reduction of 5,5’ dithiobis (2-nitrobenzoic acid) (DTNB) with glutathione (GSH) to produce a yellow compound [21] but SOD are metalloenzyme that catalyze the dismutation of superoxide anion to molecular oxygen and hydrogen peroxide [22]. MDA concentration was determined by reaction with thiobarbituric acid (TBA) in acidic medium at temperature of 95°C for 30 min to form thiobarbituric acid reactive product [23].

#### 2.3.2 Statistical analysis of the results

Data were presented as mean ± SEM and analyzed using one-way analysis of variance (ANOVA) followed by Tukey-Kramer methods for post-hoc analysis. A value of P<.05 was considered statistically significant. Graph Pad Prism 5 software (San Diego, CA, USA) was used for statistical analysis.
3. RESULTS AND DISCUSSION

3.1 Results

3.1.1 Effect of HFD on feed intake comparable to control group

Data showing the mean feed intake in (Table 1) and (Figs. 1 & 2) were significantly increased in rats of HFD during the period of the experiment compared with that of control group. Feeding of rats on HFD (Fig. 1) showed a very high significant increase (***P<0.001) in feed intake compared to normal ones that feed on normal diet during 0-16th week (induction time for obesity occur).

| Groups   | Means of feed intake (g/day/rat) |
|----------|----------------------------------|
| Control  | 216.90±12.25^a                   |
| HFD      | 327.50±22.00^b                   |

Each value is the mean±SEM means have different superscript letters indicated a significant variations.

![Graph of feed intake vs weeks](image1)

**Fig. 1.** Means of feed intake (g/day/rat) in control and HFD- induced obesity in rats (0 to 16th week). Means have a significant variations at ***P< 0.001.

3.1.2 Effect of HFD, orlistat and herbal mix on feed intake

In this study, feed intake was significantly increased during the period of the experiment in HFD rats compared with that of control group while Orlistat and herbal mix treatment tended to decrease food intake compared with HFD group (Fig. 2).

Data shows, in the 16th week HFD group, a very high significant increase (***P<0.001) in feed intake compared to control group, while treatment with Orlistat and herbal mix exerted
non-significant decrease in feed intake and weight loss. With continuous feeding of rats on
HFD and treatment with Orlistat and herbal mix, continuous increasing had occurred
(***P<0.001) in feed intake with these rats that feed on HFD than control group. Also, a very
high significant decrease (***P<0.001) in feed intake with these rats that treated with Orlistat
and herbal mix and this occurred in 20 week. At the end of the experimental study that took
22 week, we observed a very high significant increase (***P<0.001) in feed intake with HFD
group compared to control group, while treatment with Orlistat and herbal mixture showed a
very high significant decrease (**P<0.001) in feed intake.

![Graph showing feed intake in different groups of experiment](image)

Fig. 2. Means of feed intake (g/day/rat) in different groups of experiment
(18^{th}-22 week) in rats.

Means have different letters indicated significant variations.

3.1.3 Effect of diet induced obesity and treatment on body weight and body mass
index (BMI)

Our data shows that there was a higher significant in body weight during free diet of HFD
compared to control diet. It was found that HFD caused a high significant increase
(***P<0.001) in body weight and body mass index from 0-16^{th} to 18-22 wk. At the beginning
of the experiments (initial weight) all weight of two groups was the same, control & HFD, and
showed non-significant between them in weight. However these weights changed quickly
when we feed one of them on HFD and the other was fed on normal diet. We observed that
the rats that were fed on HFD had increased in body weight and body mass index compared
to normal diet (control rats). These changes occurred 0-16^{th} week and continued to the final
18-22 weeks, (Fig. 3 and 4). But these increases in BW and BMI were changed by
decreasing it with treatments of HFD with Orlistat and herbal mixture. When high fat diet
treated with Orlistat and herbal mix from 18-22 weeks a significant (*P<0.05) and a very high
significant decrease (**P<0.001) occurred in these parameters respectively according to
these figures. After the induction period of obesity finished (0-16 week), HFD began treated
with Orlistat and herbal mix in 18-22 weeks. We observed that HFD had a very high
significant increase (***P<0.001) in body weight and body mass index till the end of
experiments in 16-22 weeks compared to control group. However when treatment started in
18-22 weeks, our results showed that the treatment of HFD with Orlistat and herbal mix exerted a significant decrease in BW and BMI as shown in Figs. 3 and 4.

**Fig. 3. Means of BW in rats during all period of experiment (22 weeks)**

Means have different letters indicated significant variations. Data expressed as mean±SEM.

**Fig. 4. Means of BMI in rats during the period of the experiment (22 weeks)**

Means have different letters indicated significant variations. Data expressed as mean±SEM.

### 3.1.4 Effect of HFD, Orlistat and herbal treatment on serum cholesterol, TG, LDL and HDL in rats

Table 2 manifests the effect of HFD, Orlistat and herbal mix on serum cholesterol, triglyceride, LDL and HDL of HFD rats. HFD rats recorded a very high significant increase (**P<0.001**) in serum cholesterol, LDL. They also recorded a high significant increase (**P<0.01**) in serum triglyceride but a non-significant decrease of serum HDL as compared to normal rats. While the treatment of HFD with Orlistat recorded a very high significant
decrease (**P<0.001) in serum cholesterol and a significant decrease (*P<0.05) in serum triglyceride. Also, the treatment of HFD with herbal mix extract showed a significant decrease (*P<0.05) in serum cholesterol and triglyceride but two treatments for HDL and LDL showed a significant increase (*P<0.05) of serum HDL and a very high significant decrease (**P<0.001) of serum LDL when compared to HFD as shown in Table 2.

Table 2. Effect of HFD, orlistat and herbal treatment on serum cholesterol, TG, LDL and HDL in rats

| Groups      | TG (mg%)         | Cholesterol (mg%) | HDL (mg%)     | HDL (mg%)     |
|-------------|------------------|-------------------|---------------|---------------|
| Control     | 54.60±6.42a      | 70.30±2.75b       | 16.71±2.27a   | 40.97±2.35a   |
| HFD         | 80.00±0.65b      | 118.10±6.35c      | 55.78±4.40c   | 44.39±6.75a   |
| Orlistat    | 60.22±6.09a      | 82.78±6.75c       | 23.34±3.48c   | 63.90±4.26c   |
| Herbal Mix  | 59.56±4.55a      | 94.56±5.49c       | 29.66±3.95c   | 60.69±7.15b   |

Data is expressed as mean±SEM. Identical letters indicate non-significance between groups, while different letters indicate significance variations.

3.1.5 Effect of HFD, Orlistat and herbal treatment on kidney function tests

Table 3 manifests the effect of HFD, Orlistat and herbal mix on urea, creatinine and uric acid of HFD rats. The HFD rats exhibited no significant increase of urea and a very high significant increase (**P<0.01) of creatinine and uric acid as compared to normal rats. While the treatment of HFD with Orlistat and herbal mix exerted also a non-significant decrease of urea and a significant decrease (*P<0.05) in creatinine. In addition, they recorded a non-significant decrease uric acid when compared to HFD rats as shown in Table 3.

Table 3. Effect of HFD, Orlistat and herbal treatment on kidney function tests:

| Groups       | Urea (mg%) | Creatinine (mg%) | Uric acid (mg%) |
|--------------|------------|------------------|-----------------|
| Control      | 24.53±1.02a | 0.54±0.04a       | 1.96±0.25a      |
| HFD          | 26.22±1.55a | 0.68±0.03b       | 3.11±0.16b      |
| Orlistat     | 23.19±1.57a | 0.57±0.02a       | 2.86±0.23b      |
| Herbal Mix   | 23.81±1.25a | 0.56±0.02a       | 2.86±0.15b      |

Data is expressed as mean±SEM. Identical letters indicate non-significance between groups, while different letters indicate significance variations between groups.

3.1.6 Effect of HFD, Orlistat and herbal treatment on renal oxidative stress

Table 4 manifests the effect of HFD, Orlistat and herbal mix on renal oxidative stress of HFD rats. HFD rats exhibited a significant decrease (*P<0.05) of renal GSH and a very high significant decrease (**P<0.001) of renal SOD. They also exhibited a very high significant increase (**P<0.001) of renal MDA as compared to normal rats. While the treatment of HFD with Orlistat exerted a significant increase (*P<0.05) in renal GSH and SOD but a high significant decrease (**P<0.01) in renal MDA as compared to HFD rats. In addition, the treatment of HFD with herbal mix exerted a very high significant increase (**P<0.001) in renal GSH, a significant increase (*P<0.05) in renal SOD and a non-significant decrease in renal MDA when compared to HFD as shown in Table 4.
Table 4. Effect of HFD, Orlistat and herbal treatment on renal oxidative stress biomarkers

| Groups   | Renal GSH (mg/dl) | Renal MDA (nmol/ml) | Renal SOD (u/gm) |
|----------|-------------------|---------------------|------------------|
| Control  | 9.31±0.21a        | 35.48±3.52a         | 548.60±24.10a    |
| HFD      | 7.74±0.25b        | 63.03±1.48b         | 375.60±29.70b    |
| Orlistat | 9.37±0.22a        | 50.33±1.60c         | 499.80±27.60a    |
| Herbal   | 10.42±0.52a       | 60.17±0.02b         | 462.0±30.70a     |

Data is expressed as mean±SEM. Identical letters indicates non-significance between groups, while different letters indicated significance variations between groups.

3.2 Light Microscopic Examination of the Kidney

3.2.1 Group (1) the kidney of control rats

A histological examination of the normal kidney showed that it consists of an outer cortex an inner medulla. The kidney cortex revealed the typical histological structure of the renal corpuscle and the renal tubules. The renal corpuscle includes the glomerulus which consists of small tuft of fenestrated capillaries covered by thin diaphragm and Bowman's capsule Fig. 5a & 5b. The capsule consists of an inner visceral layer and an outer parietal layer. Also, the renal tubules consist of proximal convoluted tubules which are lined with a brush border cuboidal epithelium. While the distal convoluted tubules are lined with low and non-brush border cuboidal epithelial cells.

3.2.2 Group (2) rats treated with HFD

Light microscopic finding of kidney from HFD fed rats are summarized as follows: dilated of blood vessels Fig. 5c in addition to perivascular and periglomerular oedema infiltrated with a number of inflammatory cells was observed Fig. 5d. Also, degenerative change of renal tubules, vacuolated glomerular tuft surrounded with oedema and necrotic cells were noticed Fig. 5e and enlargement of Bowman's space Fig. 5f.

3.2.3 Group (3) rats treated with HFD with Orlistat

The present light microscopical observations clearly demonstrated that administration of the Orlistat to an adult HFD rat causes various histological alternation in the kidney tissue. These changes include: (a)-hyperemic glomerular tuft associated with swelling in the lining epithelium of renal tubules and (b)-vacular glomerular tuft with swollen endothelial cell lining the Bowman's capsule Fig. 6g. The examined kidneys showed blood vessel hypermic, necrotic cells and intertubular hemorrhage Fig. 6h & 6i. While other findings demonstratea severely congested blood vessels and a focal necrotic area with inflammatory cells infiltration Fig. 6j.

3.2.4 Group (4) rats treated with HFD with PO and nutshell extract

Animals treated with HFD plus PO and nutshell extract showed a histological picture more or less similar to controlled group fig. 6k. While others showed some hemorrhage between renal tubules fig. 6l.
Fig. 5. Photomicrograph of the kidneys sections of normal rats (a, b) and treated with HFD (c, d, e and f)

Fig (5 a&b): Photomicrograph of the kidneys’ sections of normal rats showing the glomerulus (G) and renal tubules (t). Fig (5a) H&E x 100 and Fig (5b) H&E x 400.

Fig (5 c): Photomicrograph of the kidneys’ sections of rats treated with HFD showing a dilated blood vessel (↑), perivascular oedema (O) and inflammatory cells (▲) infiltration. H & E x 400.

Fig (5 d): Photomicrograph of the kidneys’ sections of rats treated with HFD showing perivascular and periglomerular oedema infiltrated with a number of inflammatory cells (↑). H & E x 400.

Fig (5 e): Photomicrograph of the kidneys’ sections of rats treated with HFD showing degenerative change of renal tubules (RT), a vacuolated glomerular tuft (v) surrounded with oedema (O) and necrotic cells (Nc). H & E x 400.

Fig (5 f): Photomicrograph of the kidneys’ sections of rats treated with HFD showing expansion of Bowman’s capsule (↑). H & E x 400.
3.3 Discussion

Obesity is a medical condition in which excess body fat has accumulated to the extent that it may have an adverse effect on health, leading to reduced life expectancy and/or increased health problems [24]. It increases the probability of being infected with various diseases,
particularly heart disease, type 2 diabetes, obstructive sleep apnea, certain types of cancer and osteoarthritis. Newer researches point to obesity as an important risk factor for chronic kidney diseases (CKDs) [24]. Weisinger et al. [25] reported that massive obese patients developed nephrotic range proteinuria. Obesity that is related to glomerulopathy (ORG) is considered an increasing cause of end-stage renal disease (ESRD). Potential mechanisms by which obesity affects renal physiology include: altered renal hemodynamics, insulin resistance, hyperlipidemia, activation of reninangiotensin aldosterone system (RAAS), inflammation and oxidative stress. Also, increases in both glomerular filtration rate (GFR) and renal plasma flow (RPF) are observed in both obese subjects and animals [26].

It is clear in this study that there is a high significant increase of food intake in free diet of HFD during 0th-16th week and 18th-22th weeks compared to the control group (Fig. 1&2). This is may be due to HFD causing hyperphagia which similar to human cafeteria diet. The mechanisms for how saturated fat based beverages contribute to human obesity are clear in rats on an HF choice diet, plasma leptin concentrations and proopiomelanocortin mRNA increased and neuropeptide Y mRNA decreased [27]. Both palatability and PSE density contribute to fat hyperphagia and reduced satiation signaling accompanying HFD consumption which can contribute to overconsumption and often lead to obesity. The current data shows a significant increase in body weight and BMI especially in the 16th week of HFD in accordance with Akiyama et al. [28]. Increased BW and BMI may occur due to the increase of caloric intake resulting in more adipose tissue deposition than starch diet.

When we treated HFD with Orlistat and herbal mix ameliorated feed intake, significantly decreased BW and BMI. These effects of Orlistat are due to its blocking to the absorption of fat by inhibiting gastric and pancreatic lipase enzymes leading to the increased excretion of fat in faeces [29]. Also, treatment with PO has its effects on feed intake, weight gain and body mass index. This is because it contains a number of anti-oxidants and an excellent source of protein, zinc, magnesium, manganese and phosphorus. They also contain a high amount of tryptophan, an essential amino acid involved in the synthesis of a key brain chemical called serotonin which is involved in mood, sleep and appetite regulation [30]. On the other hand the PSE were screened for inhibitory effects on pancreatic lipase (PL) and lipoprotein lipase (LPL) activities as well as on lipolysis of 3T3-L1 adipocytes. It was found that PSE could prevent the body weight gain induced by feeding a HFD to male Wistar rats with 1% of PSE [11].

Our study indicated that HFD induced obesity may leads to morbidity as well as body biochemical changes. There is usually increased level of total cholesterol, LDL-C, triglycerides and decreased level of HDL-C. These results are in accordance with those of Szczygielska et al. [31]. Mean total cholesterol and triglycerides concentrations were higher in obese persons compared with normal weight people and HDL concentration was lower in obese people compared to normal and overweight individuals [31]. While treatment of HFD with Orlistat showed that patients receiving the two higher doses of Orlistat achieved significantly reduced levels of total cholesterol and LDL-C. LDL/HDLC ratio was significantly reduced in the highest dose of Orlistat group compared to placebo [32] due to inhibition of gastric and pancreatic lipases. It inhibits the hydrolysis of dietary triglycerides, consequently limiting the absorption of monoglycerides and free fatty acids. Also, the treatment of obesity in rats with PO and nutshell produced a significant decrease in serum cholesterol, serum triglycerider and a high significant decrease in serum LDL while a very high significant increase in serum HDL as compared to the HFD rats. These results are agree with that of Moreno et al. [11] and Gossell-Williams et al. [33] who found that the consumption of pumpkin seeds and nutshell extract is also beneficial in regulating serum lipid levels.
A study revealed that a diet supplemented with PO provided lower total cholesterol, lower LDL-C, lower triglycerides and higher HDL-C levels. PO may reduce LDL-C. The oil may also lower cystolic and diastolic blood pressures due to its high concentration of a phytoestrogens [33], which reduce serum cholesterol levels by the inhibition of cholesterol absorption and hepatic cholesterol esterase. On the other hand, it had been shown to lower LDL-C equivalently in hypercholesterolemic persons by suppressing cholesterol absorption. PO has a high content of linoleic acid (42.6%). PO has a good amount of oleic acid (35.3%). Oleic acid (monounsaturated fatty acid) was reported to reduce total plasma cholesterol and LDL-C. Belonging to the reduction of the isoprenaline-stimulated lipolysis by PSE suggests that PSE may be taken inside the cells, Moreno et al. [34], where it decreases the activity of HSL. Thus, the inhibition of HSL may reduce levels of circulating (FFA) linked to insulin resistance in obese patients. BW and body weight gain, were significantly lower in rats fed the high-fat diet with 1% of PSE than in those fed with the HFD alone. The rats treated with PSE showed reduced triacylglycerol content in the liver. The inhibitory activity of PSE on the lipid metabolic enzymes and the increase in fecal fat excretion suggests that PSE might be useful as a treatment to reduce the dietary fat absorption. The observed reduction in intracellular lipolytic activity of cultured 3T3-L1 adipocytes may reduce the levels of circulating free fatty acids and the reduction of the adipocyte lipolysis.

HFD caused a significant elevation in serum creatinine (Table 3); a specific indicator of glomerular function and urea level owing to consumption of HFD which result in metabolic syndrome marked by obesity, hyperlipidemia and associated with oxidative stress which leading to renal dysfunction, characterized by high level of creatinine and blood urea nitrogen. In obese people, increased serum creatinine was observed, suggesting that obesity caused elevation in renal function test and produced proteinuria, concomitantly with other risk factors such as hypertension, diabetes and dyslipidemia [35]. Renal triglyceride accumulated in obese rats accompanied by hypoaalbuminemia and elevated blood urea nitrogen. Visceral and renal fat accumulation through consumption of a HFD leads to marked renal sympathetic activation, which is related to increased responsiveness to central sympathoexcitatory effects of leptin that contributes to the development of hypertension [36]. Obesity had been associated with elevated serum uric acid. Increases in serum uric acid concentration showed positive association with BMI, WHR, Waist/thigh girth and sub-scapula triceps skin fold ratios. The risk of gout was increased among men who had been overweight in adolescence [37]. While treatment with Orlistat in our data showed that improvement in the level of renal function tests and decrease in kidney disease which found that the mechanism of action of gastrointestinal lipase inhibitors, the temporal association of accelerated renal function decline with the commencement of Orlistat. Serum uric acid, urea and creatinine levels for Orlistat – treated obese patients were decreased [38] it was reported that Orlistat treatment was beneficial for patients to get over obesity because it improved metabolic processes and therefore kidney and liver functions.

Also, treatment with herbal mix (PO) showed that decrease in renal function tests and improvement of kidney function [39]. It was observed that administration of flax/pumpkin or purslane/pumpkin seed mixtures showed an announced significant decrease in the levels of serum urea and creatinine as compared with hypercholesterolemic control group (purslane/or flax seeds were used as sources of ω-3 fatty acids). Flax seed is the richest natural source of plant lignans, which are PAF receptor antagonists. Platelet activating factor plays a key role in the mediation of inflammation, mitogenesis and alteration of glomerular permselectivity. Flaxseed could potentially inhibit various mechanisms associated with the progression of renal diseases. Flax and pumpkin seeds mixtures are rich in PUFAs and antioxidant compounds in animals. Pumpkin seeds appear to reduce levels of substances that promote
stone formation in the urine. Some researches had demonstrated that PSO could remarkably reduce bladder pressure, increase bladder compliance and reduce urethral pressure [5].

On the other hand treatment with PSE caused reduction in values of urea nitrogen and creatinine due to the active component luteolin that found in it [40]. There was a concomitant significant reduction in the elevated of marker parameters of kidney toxicity BUN and serum creatinine in luteolin pretreatment groups. This showed the efficacy of luteolin in regulating renal functions [40]. Luteolin increases the level of heme oxygenase-1 protein (HO-1) which is the inducible isoform of the HO system. It is a rate limiting enzyme converting heme into equimolar amounts of iron, carbon monoxide and biliverdin. HO-1 is thought to have antioxidant and cytoprotective roles. It was suggested that one of the mechanism of the renoprotective effect of luteolin may be related to increasing HO-1 expression and elevating antioxidant in diabetic nephropathy. PSE significantly reduced renal oxidative damage [7] and had a strong renal protective effect against glycerol-induced acute renal failure (ARF).

Dietary HFD caused a significant decrease of kidney GSH, kidney SOD and a high significant increase of kidney MDA as compared to the normal rats. Oxidative stress is caused by an imbalance between increased production of ROS and/or reduced antioxidant activity, leading to oxidative damage to cells or tissue including lipids, proteins and DNA. Studies had suggested that obesity is associated with increased oxidative stress. Oxidative stress had been commonly identified in obesity-related renal diseases and may be the mechanism underlying the initiation or progression of renal injury in obesity [41]. ROS are highly reactive molecules that oxidize lipids and proteins, cause cellular injury and promote glomerular and renal tubule injury and associated proteinuria. HFD induced obesity is accompanied by increased renal tissues oxidative stress, which is characterized by reduction in the antioxidant enzymes activities and glutathione levels, which correlate with the increase in MDA and protein carbonyl levels in most tissues [42].

While our study indicated that treatment of HFD rats with Orlistat produced a significant increase in kidney GSH, SOD and a high significant decrease in kidney MDA as compared to the drug-administrated-control rats. Garcinia, this is drug similar in action to Orlistat in weighting loss significantly decreased levels of serum MDA and renal MDA compared with HFD as result of hydroxy citric acid (HCA-SX) that inhibit ATP citrate lyase which catalyse extra mitochondrial cleavage of citrate to oxaloacetate giving acetyl COA which used in fatty acid synthesis, suggesting that Garcinia has hypolipidemic action and reduces MDA in kidney, so HCA improves lipid peroxidation [4].

On the other hand treatment of HFD rats with herbal mix produced a significant increase in kidney GSH, SOD and a high significant decrease in kidney MDA as compared to the HFD rats. Wang et al. [7] reported that pretreatment with PSE in acute renal failure (ARF) rats caused GSH in serum and renal cortical significantly increased. In addition, renal cortex homogenate MDA levels were significantly lower also, the treatment with PO contained omega-3 caused significantly lower for oxidative stress which had increased following reperfusion injury [43]. Preventive oral administration of omega-3 supplement may decrease oxidative stress, kidney dysfunction following reperfusion injury and may result in better antioxidation status.
3.4 Photomicrograph of the Kidneys Sections of Normal HFD, Orlistat and Herbal Treatment

Obesity is a chronic metabolic disorder that results from the imbalance between PSE intake and PSE expenditure characterized by enlarged fat mass and elevated lipid concentration in blood. Many attempts had been made to correct the metabolic disparity of the obesity condition, producing a number of reagents including fibrates, sibutramine (an anorectic or appetite suppressant) and Orlistat but no drug is free from severe side effects [44]. The present study demonstrates that a high-fat diet, fed for as little as 0 to 22 wk, Fig. 5 produced significant histologic, biochemical and functional changes in the kidney in comparison with normal group. These changes included expansion of Bowman’s capsule. The mechanisms responsible for the enlargement of Bowman’s space in obesity are uncertain but may be related to the marked glomerular hyperfiltration; it is interesting that the GFR was increased by almost the same percentage (38%) as the Bowman’s space increase. In our histological study, dilatation of glomerular capillaries and large blood vessels had been seen. In addition to tubular deformations, histologically detected glomerular atrophy, necrosis and oedema similar results were reported by Altunkaynak et al. [45]. The increase in the volume of the kidneys of HFD-fed rats may have resulted from oedema due to mononuclear cell infiltrations among the tubules. It is clearly understandable that dilatation may lead to a volumetric increase in the kidney. According to Hvizdos and Markham [46], Orlistat is a novel non-systemic treatment for obesity it inhibits lipases in the gastrointestinal tract, preventing the absorption of approximately 30% of dietary fat. The present study revealed that the administration Orlistat revealed that focal necrotic area with inflammatory cells infiltration and blood vessels show congestion and some renal tubules suffer from degeneration. Similar results were reported by Korzets et al. [47] who found that renal biopsy findings showed that the chronic kidney disease (CKD) was attributable to nephrocalcinosis/oxalate nephropathy, resulting in a chronic tubulo-interstitial nephropathy, while acute tubular necrosis. HFD increase serum uric acid (Table 3) that initiates renal urate crystal producing histopathological changes. Orlistat was capable of increasing urinary oxalate levels many-fold, especially in rats fed high fat or oxalate-enriched diet. A rise in the ion-activity product of calcium oxalate was also demonstrated. Interestingly, no renal depositions of oxalate were seen on examination of renal tissue at the end of the study, a fact probably explained by the relatively short period of time (6 weeks only) that the animals were treated with Orlistat. Also, in 2008, Karamadoukis et al. [48] retrospectively examined more than 800 renal biopsies, looking specifically for the combined presence of acute tubular necrosis and crystal deposition. Due to its high phosphorus content in fluted pumpkin seed oil, it is said to be a potential agent in reducing kidney bladder stone disease. HFD increased uric acid that elevate urinary acidity which increase the renal histological changes while treatment with pumpkin seed oil decreased renal acidity (toward alkalinity) due to its high phosphorus content so renal histological changes had been improved.

4. CONCLUSION

From the above results we concluded that there is a significant relationship between fatty diet intake and structural changes to the kidney with the elevated levels of urea, creatinine, uric acid, TG, LDL, and the renal injuries were associated with increased oxidative stress monitored by increased MDA level whereas GSH and SOD production decreases in addition to a decrease in the numerical density of glomeruli, tubular deformations, prominent dilatation of the renal vessels, tubules, glomerular necrosis and atrophy and basal membrane thickening. While oral administration of Orlistat and herbal mix extracts reduced the level of
circulating lipids as well as the decrease of body weights in male albino rats, these extracts improve kidney functions by decreasing oxidative stress (MDA), increasing antioxidant factors (GSH and SOD) and improve the defects that caused by obesity.

ACKNOWLEDGEMENTS

This study was supported by BeniSuef University. We appreciate the support offered by department of biochemistry.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

ETHICAL APPROVAL

For manuscripts involving animal experiments, "All authors hereby declare that "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985) were followed, as well as specific national laws where applicable. All experiments have been examined and approved by the appropriate ethics committee"

REFERENCES

1. World Health Organization. Obesity and overweight. Fact sheet Nº3; 11September 2006.
2. Gonzalez E, Gutierrez E, Morales E, Hernandez E, Andres A, Bello I, Diaz-Gonzalez R, Leiva O, Praga M. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney International. 2005;68(1):263-270. DOI:10.1111/j.1523-1755.2005.00401.x.
3. Quigley JE, Elmarakby AA, Knight SF, Manhiani MM, Stepp DW, Olearczyk JJ, Imig JD. Obesity induced renal oxidative stress contributes to renal injury in salt-sensitive hypertension." Clinical and Experimental Pharmacology and Physiology. 2009;36(7):724–728. DOI:10.1111/j.1440-1681.2009.05139.x. [PMCID]: PMC2710419.
4. Asghar M, Monjok E, Kouamou G, Ohia SE, Baghi D, Lokhandwala MF. Super citric max (HCA-SX) attenuate increase in oxidative stress, inflammation, insulin resistance, body weight in developing obese Zucker rats. Molecular and Cellular Biochemistry. 2007;304(1-2):93-99. DOI:10.1007/s11010-007-9489-3.
5. Eagles JM. Treatment of depression with pumpkin seeds. British Journal of Psychiatry. 1990;157:937-8. [PMID]: 2289114.
6. Brasaemle DL, Barber T, Wolins NE, Serrero G, Blanchette-Mackie EJ, Londos C. Adipose differentiation-related protein is an ubiquitously expressed lipid storage droplet-associated protein. Journal of Lipid Research. 1997;38(11):2249–63. [PMID]: 9392423.
7. Wang M, Zhou X, Chu Y. Effects of PSE on rats with acute renal failure. Remote Sensing, Environment and Transportation Engineering (RSETE). International Conference on Digital Object Identifier. 2011;8264–8267. DOI: 10.1109/RSETE.2011.5964079.
8. Kim MS, Kim Jk, Kwon DY, Park R. Antiadipogenic effect of garcinia extract on lipid droplets accumulation and the expression of transcription factor. Bio factor. 2004;22:193-196. PMID: 15630282 [PubMed].

189
9. The internet drug index RxList. Xenical (Orlistat 120 mg) Drug Information: Description, User Reviews, Drug Side Effects and Drug Interactions; 2012. Available: www.rxlist.com/xenical-drug.htm.

10. Kumar S, Alagawadi KR. Effect of Argyreia speciosa roots on atherogenic diet induced obesity in rats. Journal of Pharmacy Research. 2010;3(7):1524-1527.

11. Moreno DA, Ilic N, Poulev A, Raskin I. Effects of Arachis hypogaea nutshell extract on lipid metabolic enzymes and obesity parameters. Life Sciences. 2006;78(24):2797-803. PMID: 16337240. [PubMed]

12. Zuhair HA, Abd El-Fattah AA, El-Sayed MI. Pumpkin-seed oil modulates the effect of felodipine and captopril in spontaneously hypertensive rats. Pharmacological Research. 2000;41(5):555-63. PMID: 10753555 [PubMed]

13. Roberts CK, Berger JJ, Barnard RJ. Long-term effects of diet on leptin, PSE intake and activity in a model of diet-induced obesity. Journal of Applied Physiology. 2002;93:887-893. PMID: 12183482 [PubMed]

14. Drury RAB, Willington EA. Carleton's histological techniques. 8* ed. Oxford University; 1980.

15. Schettler G, Nussel E. Enzymatic Colorimetric Test for Cholesterol with Lipid Clearing Factor Determination of total cholesterol. Arb. Med. Soz. Med. Prav. Med. 1975;10:25.

16. Gordon T, Gordon M. Enzymatic method to determine the serum HDL cholesterol by Precipitant and Standard, For Use with CHOLESTEROL Liquicolor Test Kit. American Journal of Medicine. 1977; 62:707-708.

17. Fossati P, Prencipe L. Enzymatic Colorimetric Test for Triglycerides. Clinical Chemistry. 1982;28:2077.

18. Young DS. Effect of drugs on clinical lab. tests, 4th ed. Berthelot Enzymatic Colorimetric Method Determination of Urea aacc press; 1995.

19. Labbe D, Vassault A. Kinetic determination of creatinine without deproteinization in human urine, serum and plasma; 2000. Available: http://bioch.ap-hop-paris.fr/analyses/bioforma/creatinine.htm.

20. Barham D, Trinder P. Enzymatic colorimetric for Determination of uric acid. Analyst. 1972;97:142.

21. Beutler E, Duron O, Kelly MB. Colorimetric method for Determination of Glutathione reductase concentration. Journal of Laboratory and Clinical Medicine. 1963;61:882.

22. Nishikimi M, Roa NA, Yogi K. Colorimetric method for Determination of superoxide dismutase activity (SOD). Biochemical and Biophysical Research Communications. 1972;46:849-854.

23. Ohkawa H, Ohishi W, Yagi K. Colorimetric method for Determination of MDA activity. Biochemistry. 1979;95:351.

24. Haslam DW, James WP. Obesity. Lancet. 2005;366(9492):1197-1209. PMID: 16198769 [PubMed]

25. Weisinger JR, Kempson RL, Eldridge FL, Swenson RS. The nephrotic syndrome: a complication of massive obesity. Annals of Internal Medicine. 1974;81(4):440–447, doi: 10.7326/0003-4819-81-4-440.

26. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. American Journal of Renal Physiology. 2000;278(5):F817-22. PMID: 10807594 [PubMed]

27. La fleur SE, Van Rozen AJ, Groen Weg E, Adan RA. A free choice high fat, high sugar diet induces changes in arcuate neuropeptides expression that support hyperphagia. International Journal of Obesity. 2009;22(4):55-63, doi: 10.1038/ijo.2009.257, PMID: 20029382 [PubMed].
28. Akiyama T, Tachibana I, Shirohara H, Watanabe N, Otsuki M. High-fat hypercaloric diet induces obesity, glucose intolerance and hyperlipidemia in normal adult male Wistar rat. Diabetes Research and Clinical Practice. 1996;31(1–3):27–35. PMID: 8792099 [PubMed].

29. Drent ML, van der Veen EA. First clinical studies with Orlistat: a short review. Obesity Research. 1995; 3 Suppl 4: 623S-625S. PMID: 8697067 [PubMed].

30. Supplementation with PSO. Phytotherapy Research. 2008;22(7):873-7.

31. Szczysielaska A, Widomska S, Jaraszkiewicz M, Knera P, Muc K. Blood lipids profile in obese or overweight patients. Annales Universitatis Mariae Curie Skłodowska Sectio D Medicina. 2003;58(2):343-9. PMID: 15323217 [PubMed].

32. Drent ML, Larsson I, William-Olsson T, Quaade F, von Bergmann K, Strobel W, Sjöström L, van der Veen EA. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. International journal of obesity and related metabolic disorders. 1995;19(4):221-6. PMID: 7627244 [PubMed].

33. Gossell-Williams M, Lyttle K, Clarke T, Gardner M, Simon O. Supplementation with Pumpkin Seed Oil Improves Plasma Lipid Profile and Cardiovascular Outcomes of Female Non-Ovariectomized and Ovariectomized Sprague-Dawley Rats. Phytotherapy Research. 2008;22(7):873-7, doi:10.1002/ptr.2381, PMID: 18567058 [PubMed].

34. Moreno DA, Illic N, Poulev A, Brasaemle DL, Fried SK, Raskin I. Inhibitory effects of grape seed extract on lipases. Nutrition. 2003;19(10):876-879. PMID: 14559324 [PubMed].

35. Matsushita K, Yasuda G, Shouda M, Umemura S. Evaluation of renal function and protein urea body mass health examination in young obese Japanese people. Clinical and Experimental Nephrology. 2009;13(4):316-324, doi:10.1007/s10157-009-0164-8, PMID: 19377907 [PubMed].

36. Prior LJ, Eikelis N, Armitage JA, Davern PJ, Burke SL, Montani JP, Barzel B, Head GA. Exposure to a high-fat diet alters leptin sensitivity and elevates renal sympathetic nerve activity and arterial pressure in rabbits. Hypertension. 2010; 55(4):862-868. doi: 10.1161/HYPERTENSIONAHA.109.141119. PMID: 20194306 [PubMed].

37. Must A. Morbidity and mortality associated with elevated body weight in children and adolescents. The American Journal of Clinical Nutrition. 1996;63(3):445S-447S. PMID: 8615339 [PubMed].

38. Shaheen KA. Weight loss of experimental animals by brown algae in comparison with a commercial medical preparation. Faculty of Home Economics, Menoufiya University, Egypt. 2007;18–36.

39. Barakat LA, Mahmoud RH. The antiatherogenic, renal protective and immunomodulatory effects of purslane, pumpkin and flax seeds on hypercholesterolemic rats. North American Journal of Medical Sciences. 2011;3(9):411–417, doi:10.4297/najms.2011.3351. PMID: 22362450 [PubMed] PMCID: PMC3271396.

40. Sultana S, Prasad L, Jahangir T. Lutoelin ameliorates ferric nitrilotriacetic acid induced renal toxicity and tumor promotional response in rats. Indian Journal of Experimental Biology. 2009;47(5):355-360. PMID: 19579801 [PubMed].

41. Darouch S, Goucha R, Jaafoura MH, Zeki S, Ben Maiz H, Kheder A. Clinicopathological characteristics of obesity associated focal segmental glomerulosclerosis. Ultrastructural Pathology. 2011;35(4):176–182. doi: 10.3109/01913123.2011.584657. PMID: 21657818 [PubMed].

42. Noeman SA, Hamooda HE, Baalash AA. Biochemical study of oxidative stress markers in the liver, kidney and heart of high fat diet induced obesity in rats. Diabetology & Metabolic Syndrome. 2011;3(1):17. doi: 10.1186/1758-5996-3-17. PMID: 21812977 [PubMed] PMCID: PMC3174870.
43. Ashtiyani SC, Najafi H, Kabirinia K, Vahedi E, Jamebozorky L. Oral omega-3 fatty acid for reduction of kidney dysfunction induced by reperfusion injury in rats. Iranian Journal of Kidney Diseases. 2012;6(4):275-83. PMID: 22797097 [PubMed].
44. Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Journal of Vascular Health and Risk Management. 2009;5(1):441-452. PMID: 19475780 [PubMed] PMCID: PMC2686261.
45. Altunkaynak ME, Özbek E, Altunkaynak BZ, Can İ, Unal D, Unal B. The effects of high-fat diet on the renal structure and morphometric parametric of kidneys in rats. Journal of Anatomy. 2008;212(6):845–852. doi: 10.1111/j.1469-7580.2008.00902.x, PMCID: PMC2423405.
46. Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs. 1999;58(4):743-60. PMID: 10551441 [PubMed].
47. Korzets A, Gafter U, Tobar A, Chagnac A, Zingerman B, Ori Y. Furosemide, Orlistat and non-steroidal anti-inflammatory agents—too much for the kidneys to handle!. NDT Plus. 2009;2(2):167–170, doi: 10.1093/ndtplus/sfn217.
48. Karamadoukis L, Ludeman L, Williams AJ. Is there a link between calcium oxalate crystalluria, Orlistat and acute tubular necrosis? Nephrology Dialysis Transplantation. 2008;23(5):1778–1779, doi: 10.1093/ndt/gfm945. PMID: 18272781 [PubMed].

© 2014 Amin et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sciencedomain.org/review-history.php?iid=390&id=3&aid=3291